In an era where medical information travels at the speed of social media and political discourse, the line between anecdotal hope and evidence-based medicine has become increasingly blurred. A recent, comprehensive analysis published in JAMA Network Open has laid bare the profound, real-world impact that media coverage and government endorsement can have on clinical practice. The study reveals a staggering surge in prescriptions for leucovorin—a drug used primarily in chemotherapy—among children with autism, despite a complete lack of rigorous clinical evidence to support its use for this population.
The data, derived from the vast Epic Cosmos database, paints a cautionary tale of how public perception can outpace scientific validation, creating a clinical phenomenon that has left experts concerned about patient safety and the integrity of medical decision-making.
The Chronology of a Medical Trend
The rise in leucovorin prescribing was not organic; it was the result of a identifiable sequence of high-profile events that catalyzed public interest and clinical action.
The Catalyst: February 2025
The trend began in earnest following a February 2025 segment on CBS News titled, "Parents say off-label drug helped son with autism speak." The report profiled a family who claimed their child experienced dramatic, life-altering improvements in communication after being prescribed off-label leucovorin. By highlighting the narrative of a "miracle" intervention, the report ignited widespread interest among parents of children with autism—a community understandably seeking effective treatments for a condition that lacks a "cure."
The Political Amplifier: September 2025
While the media segment provided the spark, the fire was fanned in September 2025 when the White House explicitly promoted the use of leucovorin as part of a series of autism-related initiatives. This government endorsement lent an air of institutional legitimacy to a practice that remained, at that time, medically unverified.
The Plateau and Correction: 2026
Following the surge, prescription rates finally plateaued in late 2025 and January 2026. However, the damage—or at least the widespread adoption—was done. By March 2026, the FDA was forced to intervene, formally reversing the stance taken by the White House. The agency clarified that there was insufficient evidence to support the drug’s use for autism and emphasized that leucovorin is strictly approved for the treatment of FOLR1-related cerebral folate transport deficiency, an exceptionally rare hereditary condition.
Supporting Data: A 24-Fold Increase
The analysis led by Joshua Rothman, MD, of the University of California San Diego School of Medicine, provides a quantitative look at the scale of this prescribing surge. By analyzing more than 11.9 million outpatient encounters involving 838,801 children with autism, the researchers were able to track the trajectory of the trend with high precision.
Between January 2023 and January 2025, leucovorin prescriptions remained stable at a monthly average of 34.1 per 100,000 encounters. Following the initial media attention, that number began to climb. By August 2025, the rate had jumped to 335.2 per 100,000 encounters.
The most alarming data point arrived in November 2025, when the rate surged to 835.4 per 100,000—more than 24 times the historical monthly mean. Even as the rate plateaued in early 2026, the baseline remained significantly elevated compared to the pre-2025 era.
Jeremy Faust, MD, MS, editor-in-chief of MedPage Today and a researcher who independently analyzed this trend, noted the synergy between the two events: "This new paper shows that media interest alone can drive major interest in the public. And it reaffirms what we found, which was that the White House press event in September amplified that further."
Understanding Leucovorin: What is the Drug?
Leucovorin, also known as folinic acid, is a critical tool in oncology. It is frequently administered alongside methotrexate, a chemotherapy drug, to protect healthy cells from the toxic side effects of the treatment.
The theoretical link between leucovorin and autism stems from the hypothesis that some children with autism suffer from cerebral folate deficiency. Proponents of this theory suggest that by bypassing standard folate transport mechanisms, leucovorin could improve brain function in children with autism. However, the scientific consensus is stark: there is no substantive evidence that cerebral folate deficiency plays a role in the pathogenesis of autism.
Without large-scale, randomized, placebo-controlled trials, clinicians are essentially prescribing a potent drug with known side effects for a condition where its efficacy remains speculative at best.
Official Responses and Ethical Dilemmas
The role of the media in this phenomenon has been a subject of intense self-reflection within the journalism community. Celine Gounder, MD, the journalist who reported the original CBS story, noted that while the piece attempted to address the evidence gaps, dosing uncertainties, and commercial interests, the impact of the story still transcended the nuances of the reporting.
"This paper is a useful reminder that medical journalism shapes prescribing, that broadcast and print mediums have a tangible impact on how patients and clinicians understand the evidence," Gounder told MedPage Today. She emphasized that the responsibility of the media does not end when a segment airs; journalists must continue to revisit and report on the long-term outcomes and scientific updates of these medical stories.
The Clinician’s Burden
The surge also highlights the complex pressures placed on physicians. Audrey Brumback, MD, PhD, of the University of Texas at Austin, notes that the prescribing behavior is often a result of the "zone of parental discretion."
"Families are desperate to help their children," Brumback explains. "Clinicians and families develop treatment plans through shared decision-making. As clinicians, we look to guidelines from trusted sources… but families tell us they, too, have done their own research."
When faced with a parent who is convinced of a treatment’s efficacy—especially one endorsed by government officials—clinicians often find themselves caught between their duty to adhere to evidence-based medicine and the desire to maintain a therapeutic relationship with a family in need. In this instance, it appears that many clinicians prioritized the latter, choosing to prescribe the medication despite the lack of clinical backing.
Implications: A Call for Rigorous Data
The current situation with leucovorin serves as a microcosm for the challenges of modern medicine. When political entities or viral media narratives bypass the traditional, slow-moving process of scientific validation, the public suffers.
"We still don’t have large randomized trials and long-term follow-up to establish safety and efficacy," Dr. Rothman warned. "It is our duty as scientists and clinicians to generate the rigorous data needed to help families and clinicians make informed decisions."
Some researchers suggest that this surge might offer a "natural experiment" to observe the long-term effects of the drug in the autism population. However, this is an expensive and potentially dangerous way to generate data. True medical progress requires the patience of clinical trials, not the momentum of viral news cycles.
As the medical community moves forward, the "leucovorin effect" will likely be studied as a case study in medical sociology. It highlights a critical need for better communication between the scientific establishment and the public, ensuring that when families seek hope, they are guided by data that has been vetted, verified, and proven safe. Until such evidence exists, the medical community remains clear: leucovorin is not an indicated treatment for autism, and its use should be reserved for those clinical scenarios where it has been scientifically proven to provide benefit.
